You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Timeline
Attention Score in Context
Title |
Photonanozyme–Kras–ribosome combination treatment of non-small cell lung cancer after COVID-19
|
---|---|
Published in |
Frontiers in immunology, September 2024
|
DOI | 10.3389/fimmu.2024.1420463 |
Authors |
Qiaoyan Si, Mingjian Bai, Xiaolong Wang, Tianyu Wang, Yan Qin |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 August 2024.
All research outputs
#21,680,400
of 26,617,918 outputs
Outputs from Frontiers in immunology
#26,039
of 33,418 outputs
Outputs of similar age
#98,452
of 154,804 outputs
Outputs of similar age from Frontiers in immunology
#199
of 349 outputs
Altmetric has tracked 26,617,918 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 33,418 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.7. This one is in the 13th percentile – i.e., 13% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 154,804 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 22nd percentile – i.e., 22% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 349 others from the same source and published within six weeks on either side of this one. This one is in the 30th percentile – i.e., 30% of its contemporaries scored the same or lower than it.